Patents Assigned to IRONWOOD PHARMACEUTICALS
  • Publication number: 20160031903
    Abstract: Compounds of Formulae I? and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, Rajesh R. IYENGAR, Ara MERMERIAN, G-Yoon Jamie IM, Thomas Wai-Ho LEE, Colleen HUDSON, Glen Robert RENNIE, James JIA, Paul Allan RENHOWE, Timothy Claude BARDEN, Xiang Y. YU, James Edward SHEPPECK, Karthik IYER, Joon JUNG, George Todd MILNE, Kimberly Kafadar LONG
  • Publication number: 20160015644
    Abstract: Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant dispersed in a polymeric matrix. The bite acid sequestrant composition may be administered alone or in combination with at least one proton pump inhibitor, and optionally one or more agents chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyric acid-? (GABA-B) agonists, prodrugs of GABA-B agonists, acid pump antagonists, protease inhibitors and GC-C agonists.
    Type: Application
    Filed: January 14, 2014
    Publication date: January 21, 2016
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Vasu SETHURAMAN, David Bruce HEDDEN, Kristen Marie LESKOW
  • Patent number: 9205094
    Abstract: Compositions comprising a therapeutically effective amount of at least one bile acid sequestrant are disclosed for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. Exemplary bile acid sequestrants include colesevelam, colesevelam hydrochloride, colestipol, sevelamer and combinations thereof. The disclosed methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: December 8, 2015
    Assignee: IRONWOOD PHARMACEUTICALS, INC.
    Inventor: Mark G. Currie
  • Publication number: 20150342954
    Abstract: Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: August 12, 2015
    Publication date: December 3, 2015
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Charles KIM, Takashi NAKAI, Joel MOORE, Nicholas Robert PERL, G-Yoon Jamie IM, Timothy Claude BARDEN, Rajesh R. IYENGAR, Daniel P. ZIMMER, Angelika FRETZEN, Paul Allan RENHOWE
  • Patent number: 9139564
    Abstract: Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Grant
    Filed: December 26, 2012
    Date of Patent: September 22, 2015
    Assignee: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Charles Kim, Takashi Nakai, Joel Moore, Nicholas Robert Perl, G-yoon Jamie Im, Timothy Claude Barden, Rajesh R. Iyengar, Daniel P. Zimmer, Angelika Fretzen, Paul Allan Renhowe
  • Publication number: 20150250795
    Abstract: Compounds of Formula IA and Formula IB are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: April 28, 2015
    Publication date: September 10, 2015
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Charles KIM, Takashi NAKAI, Thomas Wai-Ho LEE, Joel MOORE, Nicholas Robert PERL, Jason ROHDE
  • Publication number: 20150232461
    Abstract: The present patent application discloses at least the compounds according to Formula I or Formula Ib shown below, or pharmaceutically acceptable salts thereof, wherein ring B, JB, n, JD, J, o, X, RC and RA are as described herein.
    Type: Application
    Filed: September 19, 2013
    Publication date: August 20, 2015
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Taakshi NAKAI, Nicholas Robert PERL, Joel MOORE
  • Publication number: 20150175599
    Abstract: The present disclosure relates to compounds useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders. Compounds of the invention are described in Table 1.
    Type: Application
    Filed: December 22, 2011
    Publication date: June 25, 2015
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Colleen Hudson, Timothy C. Barden, James Jia, Ara Mermerian, Bo Peng, Jane Yang, Xiang Y. Yu, Kevin Sprott, Angelika Fretzen
  • Patent number: 9061030
    Abstract: Compounds of Formula IA and Formula IB are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: June 23, 2015
    Assignee: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Charles Kim, Takashi Nakai, Thomas Wai-Ho Lee, Joel Moore, Nicholas Robert Perl, Jason Rohde
  • Patent number: 9024069
    Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt of the compound. Also described are pharmaceutical formulations thereof and methods of using the same.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 5, 2015
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Jeffrey Segal, Nisha Perez, Timothy Claude Barden
  • Publication number: 20150094272
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: August 17, 2012
    Publication date: April 2, 2015
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
  • Patent number: 8946158
    Abstract: The present invention provides peptides that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 3, 2015
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Angelika Fretzen, Marco Kessler, Daniel Zimmer
  • Publication number: 20150030697
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.
    Type: Application
    Filed: May 11, 2012
    Publication date: January 29, 2015
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler
  • Publication number: 20150018353
    Abstract: Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: December 26, 2012
    Publication date: January 15, 2015
    Applicant: IRONWOOD PHARMACEUTICALS, INC.
    Inventors: Charles Kim, Takashi Nakai, Joel Moore, Nicholas Robert Perl, G-yoon Jamie Im, Timothy Claude Barden, Rajesh R. Iyengar, Daniel P. Zimmer, Angelika Fretzen, Paul Allan Renhowe
  • Publication number: 20140349948
    Abstract: The invention provides methods for treating a patient with chronic constipation by administering a therapeutically effective dose of linaclotide.
    Type: Application
    Filed: December 23, 2013
    Publication date: November 27, 2014
    Applicants: Forest Laboratories Holdings Limited, Ironwood Pharmaceuticals, Inc.
    Inventors: Jeffrey Johnston, Angelika Fretzen, Steven Witowski, Alfredo Grossi, Hong Zhao, Bernard Joseph Lavins, Mahendra Dedhiya, Harvey Schneier
  • Publication number: 20140348942
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including inflammatory bowel disease (IBD), diverticulitis, colon cancer, an inflammatory disorder, obesity, congestive heart failure, benign prostatic hyperplasia (BPH), pain, salt retention or fluid retention.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 27, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kassler, Brian M. Cali
  • Publication number: 20140342996
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.
    Type: Application
    Filed: June 8, 2012
    Publication date: November 20, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler, Brian M. Cali
  • Patent number: 8884020
    Abstract: Indole derivatives that are useful for treating pain, inflammation and other conditions are described. Certain of the compounds are benzyl derivatives and others are benzoyl derivatives. The compounds are substituted at least at the 3 position of the indole.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: November 11, 2014
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: John Jeffrey Talley, Kevin Sprott, James Philip Pearson, G. Todd Milne, Wayne Schairer, Jane Yang, Charles Kim, Timothy Barden, Regina Lundrigan, Ara Mermerian, Mark G. Currie
  • Publication number: 20140329765
    Abstract: Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: December 16, 2013
    Publication date: November 6, 2014
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Shalina Mahajan-Miklos, Li Jing Sun
  • Publication number: 20140323448
    Abstract: Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.
    Type: Application
    Filed: April 29, 2014
    Publication date: October 30, 2014
    Applicant: Ironwood Pharmaceuticals Inc.
    Inventors: Charles KIM, Takashi NAKAI, Thomas Wai-Ho LEE, Joel MOORE, Nicholas Robert PERL, Jason ROHDE, Rajesh R. IYENGAR, Ara MERMERIAN, Angelika FRETZEN